Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03520400
Other study ID # F7374-R
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 1, 2012
Est. completion date September 30, 2019

Study information

Verified date May 2023
Source VA Office of Research and Development
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Cardiovascular disease remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Most of these deaths are due to coronary artery disease (CAD). The most common treatment for CAD is revascularization, an invasive procedure which usually involves placing a stent inside an artery that is diseased. However, exercise training is often overlooked because clinicians tend to focus on repairing the coronary circulation and the potential need for revascularization. Studies have shown that exercise training can be effective for patients with CAD and that it saves costs. In this study, invasive revascularization will be compared to a structured program of exercise training over one year. Comparisons will be made between groups for symptoms, coronary artery size and function using PET/CTA, and health care cost utilization.


Description:

Despite advances in treatment options for cardiovascular disease (CVD), this condition remains the leading cause of morbidity and mortality in the U.S. and is a major cause of disability in Veterans. Percutaneous coronary intervention (PCI) is the treatment most often used in patients with various manifestations of coronary artery disease (CAD). While it is commonly assumed that PCI also reduces mortality, randomized trials have shown that PCI has no effect on mortality except in patients being treated for acute myocardial infarction. Over the last decade, the use of PCI has increased exponentially; between 1996 and 2007, the number of PCIs performed in the US has increased more than 4-fold, from approximately 300,000 to more than 1.3 million yearly. During this time, PCI has accounted for 10% of the overall increase in Medicare expenditures. In light of the extraordinary increase in the use of this technology in recent years, questions have been raised regarding the cost-effectiveness of PCI, the extent to which PCI is overused, and whether selected patients may benefit from optimal medical therapy in lieu of PCI. Cost analyses have suggested that the current rate of increase in PCI with DES is unsustainable for the U.S. healthcare system. Given the costs associated with PCI, there have been recent efforts to compare outcomes and effectiveness of PCI against non-invasive therapy. There is a need to evaluate more judicious use of PCI, and to consider less costly interventions for at least some of the >1.3 million patients in the U.S. who undergo this procedure. Lifestyle intervention, including exercise training, is one option that has been shown to result in reduced symptoms, better exercise tolerance, improved quality of life and lower mortality. A growing body of data has demonstrated that exercise intervention improves coronary anatomy and lessens ischemia through enhanced endothelial function. While a significant proportion of health care expenditures are devoted to PCI and other invasive interventions for CVD, few health care resources are directed toward primary or secondary prevention. Recent studies have demonstrated that programs of cardiac rehabilitation, with and without implementation of intensive risk reduction, are cost effective. In part because of the financial interests associated with PCI, exercise and lifestyle intervention is rarely considered as a clinical treatment option in PCI candidates. A gap exists between the standard clinical treatment for CAD and the potential for non-invasive, less expensive and potentially more effective treatments for these patients. Previous efforts to quantify the effects of exercise and lifestyle intervention on coronary artery perfusion and anatomy have been limited to standard angiography. In recent years, improved technologies for imaging coronary perfusion and anatomy have been developed, which could provide important insights into the effects of exercise training on the heart. These include the combination of positron emission tomography and ultra-fast computed tomography angiography (CTA), commonly termed PET/CTA. PET provides information on the functional significance of anatomic stenoses by measuring myocardial blood flow and myocardial perfusion reserve. PET can also be used to evaluate coronary endothelial function by measurements of changes in myocardial blood flow in response to physical stimuli (i.e., cold pressor testing). The combination of CTA with PET also allows for improved attenuation correction. CTA, on the other hand, can noninvasively image the coronary arteries to determine the severity of stenosis and the amount of calcified and noncalcified plaque burden. The investigators have termed the current proposal "PCI Alternative Using Sustained Exercise" (PAUSE) to reflect the potential for exercise training and lifestyle intervention as alternative therapies in selected PCI candidates. Primary aim: To determine whether subjects with lesions amenable to PCI randomized to a 1 year exercise program and lifestyle intervention have greater improvement in coronary perfusion and function than those randomized to PCI. Secondary analyses: The investigators will compare exercise test responses, health care costs, quality of life, and clinical outcomes between groups.


Recruitment information / eligibility

Status Completed
Enrollment 51
Est. completion date September 30, 2019
Est. primary completion date September 30, 2019
Accepts healthy volunteers No
Gender All
Age group 45 Years to 75 Years
Eligibility Inclusion Criteria: - Stable patients who have lesions appropriate for PCI based on American Heart Association/American College of Cardiology criteria will be considered for the study. - Only patients with a good prognosis (annual mortality <2% based on VA multivariate scores (57, 58) will be considered. Exclusion Criteria: - Patients with left main disease or proximal LAD disease, or: - Unstable angina - A history of left ventricular dysfunction (EF 30%) - Pacemakers - Atrial fibrillation - Myocardial infarction within the last 3 months - Diabetes - Orthopedic problems interfering with the ability to exercise regularly

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exercise Therapy
Patients will adhere to one year of exercise therapy for the investigators' study. At minimum, subjects will aim to participate in approximately 30-60 minutes of aerobic exercise 5-7 days per week and 15-30 minutes of resistance/anaerobic exercise 2-3 times per week.

Locations

Country Name City State
United States VA Palo Alto Health Care System, Palo Alto, CA Palo Alto California

Sponsors (1)

Lead Sponsor Collaborator
VA Office of Research and Development

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Myocardial Perfusion Reserve Measurement of myocardial blood flow has only been analyzed at baseline at this time. Intravenous 13NH3 will be used as the flow tracer and serial imaging with PET will be performed. Measurements will be performed at baseline, and after pharmacologic stress with dipyridamole. Myocardial blood flow at rest and following dipyridamole infusion will be expressed as ml flow/100 g/min. The myocardial perfusion reserve will be calculated as the ratio of the myocardial blood flow during stress (e.g. after dipyridamole) and the myocardial blood flow at rest. Commercially available software (Emory tool box) will be used to quantitatively analyze PET myocardial perfusion images. baseline and 1 year
Secondary Peak VO2 Peak VO2 will be determined at baseline and 1 year on a treadmill using an individualized ramp protocol with collection of continuous ventilatory gas exchange responses. baseline and after 1 year
See also
  Status Clinical Trial Phase
Completed NCT02122198 - Vascular Mechanisms for the Effects of Loss of Ovarian Hormone Function on Cognition in Women N/A
Completed NCT02502812 - Bioequivalence Study of Clopidogrel 75 mg in Two Tablet Formulations Relative to Reference Tablet in Healthy Subjects Phase 1
Recruiting NCT04216342 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Fx-5A in Healthy Volunteers Phase 1
Completed NCT03654313 - Single and Multiple Ascending Doses of MEDI6570 in Subjects With Type 2 Diabetes Mellitus Phase 1
Completed NCT03646656 - Heart Health Buddies: Peer Support to Decrease CVD Risk N/A
Completed NCT02081066 - Identification of CETP as a Marker of Atherosclerosis N/A
Completed NCT02147626 - Heart Health 4 Moms Trial to Reduce CVD Risk After Preeclampsia N/A
Not yet recruiting NCT06405880 - Pharmacist Case Finding and Intervention for Vascular Prevention Trial N/A
Recruiting NCT03095261 - Incentives in Cardiac Rehabilitation N/A
Completed NCT02589769 - Effects of Reduction in Saturated Fat on Cholesterol and Lipoproteins in Lean and Obese Persons N/A
Not yet recruiting NCT02578355 - National Plaque Registry and Database N/A
Completed NCT02998918 - Effects of Short-term Curcumin and Multi-polyphenol Supplementation on the Anti-inflammatory Properties of HDL N/A
Completed NCT02711878 - Healing Hearts and Mending Minds in Older Adults Living With HIV N/A
Completed NCT02868710 - Individual Variability to Aerobic Exercise Training N/A
Recruiting NCT02885792 - Coronary Artery Disease in Patients Suffering From Schizophrenia N/A
Completed NCT02640859 - Investigation of Metabolic Risk in Korean Adults
Completed NCT02657382 - Mental Stress Ischemia: Biofeedback Study N/A
Completed NCT02272946 - Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk Phase 2
Completed NCT02652975 - Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium N/A
Recruiting NCT02265250 - Pilot Study-Magnetic Resonance Imaging for Global Atherosclerosis Risk Assessment